Forte Biosciences, Inc.
FBRX
$12.65
-$1.01-7.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 61.81% | -23.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 119.34% | -14.81% | |||
| Operating Income | -119.34% | 14.81% | |||
| Income Before Tax | -118.81% | 14.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -118.81% | 14.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -118.81% | 14.74% | |||
| EBIT | -119.34% | 14.81% | |||
| EBITDA | -119.47% | 14.83% | |||
| EPS Basic | -17.62% | 74.29% | |||
| Normalized Basic EPS | -17.62% | 74.29% | |||
| EPS Diluted | -17.62% | 74.29% | |||
| Normalized Diluted EPS | -17.62% | 74.29% | |||
| Average Basic Shares Outstanding | 86.03% | 231.64% | |||
| Average Diluted Shares Outstanding | 86.03% | 231.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||